Topical Treatments:

• Emollients
• Corticosteroids
• Vitamin D analogs
• Calcineurin Inhibitors
• Other Topical Agents

Systemic Treatments:

• Methotrexate
• Oral Retinoids
• Cyclosporine A

Biological Treatments:

• Enbrel (Etanercept)
• Humira (Adalimumab)
• Remicade (Infliximab)
• Stelara (Ustekinumab)

Phototherapy

• PUVA
• UVB
• Excimer Laser & Light

Infliximab

Infliximab (trade name Remicade) is a chimeric (75% human, 25% murine) IgG1 monoclonal antibody which targets TNF alpha.  

Infliximab is given as infusions. Infusions are administered at week 0, 2, and 6, and every 8 weeks thereafter. Infliximab is superior in the treatment of pustular psoriasis to other anti-TNF-α therapies such as etanercept or adalimumab since it can be expected to act more quickly and is more likely to achieve a response.

The most common side effects are adverse reactions to I.V. administration of the drug, delayed hypersensitivity associated with repeated administration, and infection and cardiac impairment which is only observed in patients with known heart insufficiency.